Related references
Note: Only part of the references are listed.Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes
Juliana Schwaab et al.
ANNALS OF HEMATOLOGY (2015)
The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis
Philipp Erben et al.
ANNALS OF HEMATOLOGY (2014)
Comprehensive mutational profiling in advanced systemic mastocytosis
Juliana Schwaab et al.
BLOOD (2013)
Long-term follow-up of treatment with imatinib in eosinophilia-associated myeloid/lymphoid neoplasms with PDGFR rearrangements in blast phase
G. Metzgeroth et al.
LEUKEMIA (2013)
Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field
Peter Valent et al.
EXPERT REVIEW OF HEMATOLOGY (2012)
ICON: Eosinophil Disorders
Peter Valent et al.
WORLD ALLERGY ORGANIZATION JOURNAL (2012)
Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3
Christoph Walz et al.
BLOOD (2011)
Next-Generation Sequencing Technology Reveals a Characteristic Pattern of Molecular Mutations in 72.8% of Chronic Myelomonocytic Leukemia by Detecting Frequent Alterations in TET2, CBL, RAS, and RUNX1
Alexander Kohlmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
The 2008 World Health Organization Classification System for Myeloproliferative Neoplasms Order Out of Chaos
Ayalew Tefferi et al.
CANCER (2009)
Identification of a MYO18A-PDGFRB Fusion Gene in an Eosinophilia-Associated Atypical Myeloproliferative Neoplasm with a t(5;17)(q33-34;q11.2)
Christoph Waz et al.
GENES CHROMOSOMES & CANCER (2009)
The molecular anatomy of the FIP1L1-PDGFRA fusion gene
C. Walz et al.
LEUKEMIA (2009)
Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders
C. Walz et al.
LEUKEMIA (2008)
Hypereosinophilic syndrome: Another face of janus?
Issa J. Dahabreh et al.
LEUKEMIA RESEARCH (2008)
Screening for JAK2 V617F point mutation in patients with hypereosinophilic syndrome-in response to ‘Hypereosinophilic syndrome: Another face of janus?’ by Dahabreh et al. published in Leukemia Research, in press
Grzegorz Helbig et al.
LEUKEMIA RESEARCH (2008)
Management of Hypereosinophilic syndrome - A prospective study in the era of molecular genetics
Issa J. Dahabreh et al.
MEDICINE (2007)
KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities
Irina Maric et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2007)
Tyrosine kinases as therapeutic targets in BCR-ABL negative chronic myeloproliferative disorders
Andreas Reiter et al.
CURRENT DRUG TARGETS (2007)
Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RA4P2-PDGFRA fusion gene
Christoph Walz et al.
GENES CHROMOSOMES & CANCER (2006)
Eosinophilia: secondary, clonal and idiopathic
A Tefferi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders
AV Jones et al.
BLOOD (2005)
The t(8;17)(p11;q23) in the 8p11 myeloproliferative syndrome fuses MYO18A to FGFR1
C Walz et al.
LEUKEMIA (2005)
JAK/STAT-dependent gene regulation by cytokines
D Hebenstreit et al.
DRUG NEWS & PERSPECTIVES (2005)
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome
J Cools et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Share Paper
